These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 23343830

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64. Molecular mechanisms of the progression of myelodysplastic syndrome to secondary acute myeloid leukaemia and implication for therapy.
    Dan C, Chi J, Wang L.
    Ann Med; 2015 May; 47(3):209-17. PubMed ID: 25861829
    [Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study.
    Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E, Zhao L, Patel K, Neelapu S, Gumbs C, Bueso-Ramos C, DiNardo CD, Colla S, Ravandi F, Zhang J, Huang X, Wu X, Samaniego F, Garcia-Manero G, Futreal PA.
    Lancet Oncol; 2017 Jan; 18(1):100-111. PubMed ID: 27923552
    [Abstract] [Full Text] [Related]

  • 69. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era?
    Liu Y, Bewersdorf JP, Stahl M, Zeidan AM.
    Blood Rev; 2019 Mar; 34():67-83. PubMed ID: 30553527
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 72.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75. Current status and trends in the diagnostics of AML and MDS.
    Shumilov E, Flach J, Kohlmann A, Banz Y, Bonadies N, Fiedler M, Pabst T, Bacher U.
    Blood Rev; 2018 Nov; 32(6):508-519. PubMed ID: 29728319
    [Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Comprehensive analysis of factors impacting risks and outcomes of therapy-related myeloid neoplasms following breast cancer treatment.
    Sevcikova K, Zhuang Z, Garcia-Manero G, Alvarez RH, Kantarjian HM, Mego M, Albarracin C, Tang G, Strom SS, Medeiros LJ, Hortobagyi GN, Reuben JM, Khoury JD.
    Leukemia; 2016 Jan; 30(1):242-7. PubMed ID: 25975189
    [No Abstract] [Full Text] [Related]

  • 79.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 80.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.